Lupin Limited has entered into a non-exclusive patent license agreement with Takeda Pharmaceutical Company Limited to commercialize Vonoprazan Tablets in India. Under this agreement, Lupin will market the drug under the brand name Lupivon® in two strengths: 10 mg and 20 mg.
Vonoprazan, a novel potassium-competitive acid blocker (P-CAB), is used for the treatment of Acid Peptic Disorders, including Gastroesophageal Reflux Disease (GERD) and Peptic Ulcer Disease (PUD). Unlike traditional treatments, Vonoprazan provides full proton pump inhibition with the first dose and has a longer duration of action. It is also approved for the treatment of reflux esophagitis, gastric ulcers, duodenal ulcers, and as part of Helicobacter pylori eradication therapy in India.
Rajeev Sibal, President of India Region Formulations at Lupin, stated, “Commercializing Vonoprazan aligns with our commitment to offering innovative treatments that address the unmet needs of patients in India.”
No further details were provided about the financial aspects of the agreement.
